Abstract
Objective To compare and analyze the efficacy and safety of amisulpride and risperidone in the treatment of patients with first-episode schizophrenia(FES). Methods 80 patients with FES were randomly divided into the observation group (n=40, orally given amisulpride) and the control group (n=40, orally given risperidone) according to random number table.The total effective rate, positive and negative symptoms scale (PANSS), adverse reaction rate of two groups were compared. Results 1 week after treatment, the negative symptoms score of the observation group was significantly lower than that of the control group[(20.89±3.07)points vs.(18.15±3.64)points, t=3.639, P=0.001].8 weeks after treatment, the PANSS scores and factor score of the two groups had no significant differences(all P>0.05). The total effective rate and adverse reaction rate of the observation group were 90.00%, 17.50% respectively, which of the control group were 82.50%, 27.50% respectively, there were no statistically significant differences (χ2=0.949, P=0.330; χ2=1.147, P=0.284). Conclusion Amisulpride and risperidone has similar efficacy and safety in the treatment of patients with FES, but amisulpride has better early effect in improving negative symptoms. Key words: Schizophrenia; Amisulpride; Risperidone
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call